WO2005124350A1 - Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases - Google Patents
Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases Download PDFInfo
- Publication number
- WO2005124350A1 WO2005124350A1 PCT/IT2004/000352 IT2004000352W WO2005124350A1 WO 2005124350 A1 WO2005124350 A1 WO 2005124350A1 IT 2004000352 W IT2004000352 W IT 2004000352W WO 2005124350 A1 WO2005124350 A1 WO 2005124350A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- apc
- fitc
- autoimmune
- prognosis
- Prior art date
Links
- 238000000684 flow cytometry Methods 0.000 title claims abstract description 24
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 21
- 238000004393 prognosis Methods 0.000 title claims description 16
- 230000001363 autoimmune Effects 0.000 title claims description 14
- 238000009169 immunotherapy Methods 0.000 title claims description 14
- 238000003745 diagnosis Methods 0.000 title claims description 10
- 208000030289 Lymphoproliferative disease Diseases 0.000 title claims description 6
- 238000010200 validation analysis Methods 0.000 title claims 13
- 230000002489 hematologic effect Effects 0.000 title description 6
- 208000014951 hematologic disease Diseases 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 24
- 208000023661 Haematological disease Diseases 0.000 claims abstract description 17
- 238000004458 analytical method Methods 0.000 claims abstract description 15
- 230000001900 immune effect Effects 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 53
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 21
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 15
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 15
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 13
- 102100033467 L-selectin Human genes 0.000 claims description 13
- 230000001413 cellular effect Effects 0.000 claims description 12
- 238000010186 staining Methods 0.000 claims description 12
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 7
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 7
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 7
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 7
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 7
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 3
- 101100181107 Homo sapiens KLRB1 gene Proteins 0.000 claims description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 3
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims description 3
- 101150033443 Klrb1a gene Proteins 0.000 claims description 3
- 229930191564 Monensin Natural products 0.000 claims description 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000003092 anti-cytokine Effects 0.000 claims description 3
- 230000016396 cytokine production Effects 0.000 claims description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 239000003226 mitogen Substances 0.000 claims description 3
- 229960005358 monensin Drugs 0.000 claims description 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- 230000008823 permeabilization Effects 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 238000009738 saturating Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000007619 statistical method Methods 0.000 claims description 3
- 230000001960 triggered effect Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 4
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 210000005170 neoplastic cell Anatomy 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 6
- 208000037581 Persistent Infection Diseases 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 230000001173 tumoral effect Effects 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/42—Low-temperature sample treatment, e.g. cryofixation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1477—Multiparameters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Definitions
- This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations; these antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases).
- the increased knowledge on how the immune system works has brought, in recent years, to a better understanding of the pathogenesis of many diseases, and, consequently, to new therapeutic approaches.
- the interactions between the different components of the immune system are indeed very complex, and new technologies have revealed that cellular populations Which apparently seem homogeneous are in fact composed of several subpopulations with different phenotypes and functions.
- the cells of the immune system circulate in the blood and the lymph which can also migrate to tissue to protect the organism efficiently. Lymphocytes specifically recognise and respond to foreign antigens, while phagocytes and granulocytes are classified as "inflammatory" cells, and they play a major role in the innate immune response.
- lymphocytes appear to be macroscopically homogeneous, they can actually be divided in distinct subpopulations: in the first place one must distinguish between B-lymphocytes, which produce antibodies, and T lymphocytes. Based on expression of surface molecules, the latter can be further divided in CD4+ "helper” cells and CD8+ cytotoxic cells. Both CD4+ and CD8+ cells comprise subsets, which have not yet encountered a foreign antigen, so called “na ⁇ ve" cells, and memory cells, which represent the expanded pool of antigen experienced cells. But these subsets are still heterogeneous: indeed some memory cells produce proinflammatory proteins, while other tend to regulate and to switch off the immune response.
- the complexity of the immune system is such that the identification of cellular subsets with unique functional characteristics requires the simultaneous measurement of multiple parameters on each single cell.
- multiparametric flow cytometry it is possible to measure the presence of surface markers, which permit the identification of distinct cellular subsets: for instance, during a viral infection, it is possible to identify virus-specific cells activated by the infection and to follow them during the anti-viral response.
- virus-specific cells activated by the infection and to follow them during the anti-viral response.
- the cells of the immune system become activated and acquire the functions which permit the elimination of the offending agent.
- adhesion molecules which enable the cells of the immune system to interact with the endothelial cells lining the capillaries: this interaction represents the initial step of the migration process by which the cells of the immune system gain access to inflamed tissues.
- the study of the membrane receptors expressed by the different subsets of lymphocytes represents a powerful tool for the evaluation of the "immunological status" of an individual.
- autoimmune diseases are the results of the dysregulation of the complex interactions between cells of the immune system, so these pathologies represent a good target for studies involving the definition of fine cellular subsets.
- Flow cytometry represents the ideal tool for the study of non adherent cells (in suspension), and can be used also for the study of lymphoid tissues, from which single cell suspensions can be easily obtained. Data obtained with flow cytometry - both concerning the distribution of the different cellular subsets and the expression of multiple cellular markers are then evaluated with powerful software.
- Fig. 1 show the multiparametric analysis of CD3+CD8+ lymphocytes obtained from the peripheral blood of a healthy subject.
- Fig.2. show the multiparametric analysis of CD3+CD8+ lymphocytes in an MS patient
- Fig.3. show the analysis of the ability of CD3+CD8+ lymphocytes to produce the inflammatory cytokine interferon gamma (IFN ⁇ ).
- This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations.
- These antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases).
- Antibodies are aliquoted in small tubes at predetermined concentrations, and then lyophilised.
- Antibodies which we have tested are: CD3 PE-Cy7, CD8 PE-Cy7, CD8 PE-TxRed, CD45RA PE-TxRed, CD62L PE-TxRed, CD45RO PE-TxRed, CD8 beta PE, CD49dFlTC, NKRP1A PE, CD3 FITC, CD3 PE, CD8 FITC, CD8 PE, CD8 CyChrome, CD8 APC, CD4 FITC, CD4 APC, CD62L PE-Cy5, CD62L APC, CD162 PE, CCR7 PE, CD45RO FITC, CD11a PE, CD11a APC, CD49d PE, CD8 APC-Cy7, CDHa ' FITC, CD45RA PE-Cy5, CD5 PE-Cy5, CD23 PE-TxRed, CD19 PE-Cy7, CD19 APC- Cy7, CD79b APC, CD38 PE, kappa FITC, lambda PE, F
- Antibodies are used are optimal predetermined concentrations, (usually 0,25 ⁇ g/ml). Each new antibody lot is accurately tested in serial dilutions, and antibodies are aliquoted in 1 ,5 ml tubes in different combinations. Tubes are then put in the speedvac, until completely lyophilised (20 minutes). Before use each antibody combinations is reconstituted with saline solution, and added to the tube containing cells to be analyzed. For each antibody combination, 2x10 6 cells are stained. This method can be used for staining of whole blood or of peripheral blood lymphocytes (PBLs) obtained from centrifugation on a density gradient.
- PBLs peripheral blood lymphocytes
- heparinized blood will be diluted with 1 volume of RPMI media and gently layered over the Fycoll-Hypaque (Pharmacia). Following centrifugation at 660g for 30 minutes, cells at the interface of the gradient will be collected and washed three times in medium. After the final wash cells will be resuspended in PBS with 1% human serum. For each labelling cells will be resuspended in a volume of 100 ⁇ l. All antibodies will have been tested at saturating conditions, to exclude differences in staining.
- Samples will then be acquired at the flow cytometer using constant instrument settings, obtained by a careful daily calibration of the instruments with beads and by the use of appropriate compensation controls (beads coated with the antibodies used in the stainings). For each sample 1x106 events will be acquired, in order to guarantee an appropriate representation of all cellular subsets, and allowing significant statistical analysis.
- To study cytokine production we will follow the procedure of intracellular staining, as established in our laboratory. Briefly, cells are plated at a density of 2x10 6 /ml in 96 well plates and triggered with either mitogens (PHA, PMA+ionomycin) or antibodies directed against cell surface molecules (such as CD3), for 6 hours at 37°C, in the presence of monensin (10 mM).
- Flow cytometric analysis permits not only the phenotypic analysis of cellular subpopulations r but also the ability of each subpopulation to produce soluble factors which modulate the immune response (Fig. 3).
- the panel of cytokine produced by each cell type provides important information on the immunological status of the patient, and can be used as a "marker" of the efficacy of immunomodulatory treatments.
- this invention may be used for the diagnosis of hematologic and lymphoproliferative disorders.
- flow cytometry is a powerful tool used for the characterization of neoplastic cells present in these diseases.
- the ability to simultaneously measure multiple markers on each ' single cell enables to carry out a detailed analysis of tumoral cells, and to perform an accurate diagnosis.
- the diagnosis of hematologic tumours requires an accurate characterization of the neoplastic clone, since treatment and prognosis depend closely on the diagnosis.
- a standard panel of antibodies specific for membrane or cytoplasmic markers is used in order to define the lineage and differentiation stage of the neoplastic clone (Tab.1).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations. These antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases). Antibodies are aliquoted in small tubes at predetermined concentrations, and then lyophilised.
Description
USE OF MULT I PARAMETRIC FLOW CYTOMERY FOR THE DIAGNOSIS , PROGNOSIS , AND VALIDATIO N OF IMMUNOTHERAPIES IN AUTOIMMUNE , HEMATOLOGIC, AND LYMPHOPROLIFERATIVE DISEASE S
Technical field This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations; these antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed study of neoplastic cell populations (when screening for haematological diseases).
Description of the Related Art
The increased knowledge on how the immune system works has brought, in recent years, to a better understanding of the pathogenesis of many diseases, and, consequently, to new therapeutic approaches. The interactions between the different components of the immune system are indeed very complex, and new technologies have revealed that cellular populations Which apparently seem homogeneous are in fact composed of several subpopulations with different phenotypes and functions.
The cells of the immune system circulate in the blood and the lymph which can also migrate to tissue to protect the organism efficiently. Lymphocytes specifically recognise and respond to foreign antigens, while phagocytes and granulocytes are classified as "inflammatory" cells, and they play a major role in the innate immune response. Although lymphocytes appear to be macroscopically homogeneous, they can actually be divided in distinct subpopulations: in the first place one must distinguish between B-lymphocytes, which produce antibodies, and T lymphocytes. Based on expression of surface molecules, the latter can be further divided in CD4+ "helper" cells and CD8+ cytotoxic cells. Both CD4+ and CD8+ cells comprise subsets, which have not yet encountered a foreign antigen, so called "naϊve" cells, and memory cells, which represent the expanded pool of antigen experienced cells. But these subsets are still heterogeneous: indeed some memory cells produce proinflammatory proteins, while other tend to regulate and to switch off the immune response. Thus, it is clear that the complexity of the immune system is such that the identification of cellular subsets with unique functional characteristics requires the simultaneous measurement of multiple parameters on each single cell. With multiparametric flow cytometry it is possible to measure the presence of surface markers, which permit the identification of distinct cellular subsets: for instance, during a viral infection, it is possible to identify virus-specific cells activated by the infection and to follow them during the anti-viral response. Thus, it is possible to study the initial expansion of these cells, to evaluate the panel of anti-viral proteins produced, and finally to monitor the contraction of the virus specific population and the return to the steady state, with the maintenance of a memory population able to respond more rapidly and vigorously in. the case of re-infection.
During the immune response, be it directed against infectious agents, tumours, or, in the case of autoimmune disorders, against tisues of the host, the cells of the immune system become activated and acquire the functions which permit the elimination of the offending agent. For instance, it is crucial to study the expression of adhesion molecules which enable the cells of the immune system to interact with the endothelial cells lining the capillaries: this interaction represents the initial step of the migration process by which the cells of the immune system gain access to inflamed tissues. The study of the membrane receptors expressed by the different subsets of lymphocytes represents a powerful tool for the evaluation of the "immunological status" of an individual. Notably, autoimmune diseases are the results of the dysregulation of the complex interactions between cells of the immune system, so these pathologies represent a good target for studies involving the definition of fine cellular subsets.
For instance, in the case of Multiple Sclerosis, an autoimmune disorder of the nervous system in which the cells of the immune system erroneously attack the myelin sheath, it would be useful to delineate a strategy by which the different cellular subsets can be uniquely identified andJbllowed in time with the progression of the disease. Flow cytometry is also a fundamental tool for the diagnosis and characterization of hematologic and lymphoproliferative disorders. This technology indeed represents a necessary complement for the traditional diagnostic tools based on the use of the microscope, and it also adds finer discrimination abilities which can not be achieved with other diagnostic tools. Flow cytometry represents the ideal tool for the study of non adherent cells (in suspension), and can be used also for the study of lymphoid tissues, from which single cell suspensions can be easily obtained. Data obtained with flow cytometry - both concerning the distribution of the different cellular subsets and the
expression of multiple cellular markers are then evaluated with powerful software.
The identification of tumoral clones, the study of the expression of tumoral antigens by leukemias, the measurement of cell cycle and the detection of intracellular antigens represent useful applications of flow cytometry in haematology. Generally, in clinical labs where blood samples obtained from patients with hematologic diseases, diagnosis is made using 4 or 5 parameter-flow cytometry (2 or three colours). Given that neoplastic cells may coexpress numerous markers, the possibility to perform multiparametric analyses ' with 7 colours permits a more accurate definition of. neoplastic populations thus allowing a faster and more precise analysis.
Brief description of the drawings
Fig. 1 show the multiparametric analysis of CD3+CD8+ lymphocytes obtained from the peripheral blood of a healthy subject.
Fig.2. show the multiparametric analysis of CD3+CD8+ lymphocytes in an MS patient
Fig.3. show the analysis of the ability of CD3+CD8+ lymphocytes to produce the inflammatory cytokine interferon gamma (IFNγ).
Detailed description of the preferred embodiment
This invention concerns a method which allows to perform flow cytometric analysis using determined antibody combinations. These antibodies are conjugated with different fluorochromes, and the antibody combinations include several panels which allow to perform an analysis of the immunological status of the individual (in case of screening for autoimmune disorders or chronic infections) or a detailed
study of neoplastic cell populations (when screening for haematological diseases). Antibodies are aliquoted in small tubes at predetermined concentrations, and then lyophilised. Antibodies which we have tested are: CD3 PE-Cy7, CD8 PE-Cy7, CD8 PE-TxRed, CD45RA PE-TxRed, CD62L PE-TxRed, CD45RO PE-TxRed, CD8 beta PE, CD49dFlTC, NKRP1A PE, CD3 FITC, CD3 PE, CD8 FITC, CD8 PE, CD8 CyChrome, CD8 APC, CD4 FITC, CD4 APC, CD62L PE-Cy5, CD62L APC, CD162 PE, CCR7 PE, CD45RO FITC, CD11a PE, CD11a APC, CD49d PE, CD8 APC-Cy7, CDHa 'FITC, CD45RA PE-Cy5, CD5 PE-Cy5, CD23 PE-TxRed, CD19 PE-Cy7, CD19 APC- Cy7, CD79b APC, CD38 PE, kappa FITC, lambda PE, FMC7 FITC, CD20 PE-Cy7.
Antibodies are used are optimal predetermined concentrations, (usually 0,25μg/ml). Each new antibody lot is accurately tested in serial dilutions, and antibodies are aliquoted in 1 ,5 ml tubes in different combinations. Tubes are then put in the speedvac, until completely lyophilised (20 minutes). Before use each antibody combinations is reconstituted with saline solution, and added to the tube containing cells to be analyzed. For each antibody combination, 2x106 cells are stained. This method can be used for staining of whole blood or of peripheral blood lymphocytes (PBLs) obtained from centrifugation on a density gradient. Briefly, heparinized blood will be diluted with 1 volume of RPMI media and gently layered over the Fycoll-Hypaque (Pharmacia). Following centrifugation at 660g for 30 minutes, cells at the interface of the gradient will be collected and washed three times in medium. After the final wash cells will be resuspended in PBS with 1% human serum. For each labelling cells will be resuspended in a volume of 100 μl. All antibodies will have been tested at saturating conditions, to exclude differences in staining. Samples will then be acquired at the flow cytometer using constant instrument settings, obtained by a careful daily calibration of the instruments with beads and by the use of
appropriate compensation controls (beads coated with the antibodies used in the stainings). For each sample 1x106 events will be acquired, in order to guarantee an appropriate representation of all cellular subsets, and allowing significant statistical analysis. To study cytokine production we will follow the procedure of intracellular staining, as established in our laboratory. Briefly, cells are plated at a density of 2x106/ml in 96 well plates and triggered with either mitogens (PHA, PMA+ionomycin) or antibodies directed against cell surface molecules (such as CD3), for 6 hours at 37°C, in the presence of monensin (10 mM). At the end of the incubation period, cells will be collected, spun, and staining of extracellular markers will be performed, followed by two washes. Samples will then be fixed with 4% paraformaldehyde in PBS for 10 min at 40C, and permeabilized by washing twice with a solution containing PBS (without Ca++ and Mg++), 1% FBS, and 0.1% saponin at pH 7.4. Cells will be resuspended in permeabilization buffer plus fluorochrome-conjugated anticytokine antibody (1μg per ml) for 30 min at 4°C in the dark. Cells will be washed twice, resuspended in 250 μl of staining buffer (PBS, 1% FBS, 0.01% sodium azide) and analyzed by FACS. This invention has been successfully used in our laboratory for the study of- the distribution of different cell subsets in healthy individuals and in patients with autoimmune diseases. The accurate analysis of the different cellular subsets allows to identify a disequilibrium of the immune system (due for instance to the presence of an autoimmune disease, or to a chronic infection which determines a persistent stimulation of immune cells). Moreover based on our studies, it is possible to say that the results of a detailed phenotypic analysis can also be taken in consideration for the prognosis of the disease. For instance we have shown that multiple sclerosis patients during the acute phase of the disease show a very high proportion of "naϊve" and perforin+ effector T cells, and this percentage varies in the course of the disease (Fig.2)
Flow cytometric analysis permits not only the phenotypic analysis of cellular subpopulationsr but also the ability of each subpopulation to produce soluble factors which modulate the immune response (Fig. 3). The panel of cytokine produced by each cell type provides important information on the immunological status of the patient, and can be used as a "marker" of the efficacy of immunomodulatory treatments. Moreover, this invention may be used for the diagnosis of hematologic and lymphoproliferative disorders. As mentioned above, flow cytometry is a powerful tool used for the characterization of neoplastic cells present in these diseases. The ability to simultaneously measure multiple markers on each' single cell enables to carry out a detailed analysis of tumoral cells, and to perform an accurate diagnosis. The diagnosis of hematologic tumours requires an accurate characterization of the neoplastic clone, since treatment and prognosis depend closely on the diagnosis. Usually a standard panel of antibodies specific for membrane or cytoplasmic markers is used in order to define the lineage and differentiation stage of the neoplastic clone (Tab.1).
Discrimination between B and T lymphocytes CD2 CD3 I CD5 CD7 CD10 I CD19 CD20 CD24 B cells + + T cells + +
In clinical labs these analyses are performed using two or three markers in each staining. With this invention it is possible to analyze simultaneously 7 markers on each single cell, with the following advantages: 1. Less sample needs to be used in each test; 2. Saving of reagents; 3. Accurate definition of the neoplastic cells; 4. Test can be performed in a smaller amount of time.
Again, a set of pre-defined antibody combinations are used in order to accurately define cell populations.
Claims
Claims
1. Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases. This method is characterized by the ability to use different fluorochrome-conjugated antibody combinations which enable to perform an analysis of the individual's immunological status; the antibodies are aliquoted in predetermined concentrations and lyophilized. At the moment of use, each antibody combination is reconstituted by the addition of saline solution, and added to the tube containing the cells to be analyzed. For each antibody combination 2x106 cells are stained. Each antibody is tested and used in saturating concentration so as to avoid differences in sample staining. Samples are then analyzed at the flow cytometer using constant instrument setting obtained with a careful daily calibration with beads. For each sample 1x106 events are acquired in order to achieve an appropriate representation of all cellular subsets and to allow significant statistical analysis.
2.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that the antibodies whose efficacy has been tested are: CD3 PE-Cy7, CD8 PE-Cy7, CD8 PE-TxRed, CD45RA PE-TxRed, CD62L, PE-TxRed, CD45RO PE-TxRed, CD8 beta PE, CD49dFITC, NKRP1A PE, CD3 FITC, CD3 PE, CD8 FITC, CD8 PE, CD8 CyChrome, CD8
APC, CD4 FITC, CD4 APC, CD62L PE-Cy5, CD62L APC, CD162 PE, CCR7 PE, CD45RO FITC, CD11a PE, CD11a APC, CD49d PE, CD8 APC-Cy7, CD11a FITC, CD45RA PE-Cy5, CD5 PE-Cy5, CD23 PE- TxRed, CD19 PE-Cy7, CD19 APC-Cy7, CD79b APC, CD38 PE, kappa FITC, lambda PE, FMC7 FITC, CD20 PE-Cy7. Two examples of antibody combinations used are: a) for haematological diseases, Mix 1 = CD19 CD20 CD79b, CD5, CD23, CD38, FMC7, and b) for the study of Multiple Sclerosis Mix 2= CD3 CD8 CCR7 CD45RA CD11a CD62L CD27. 3. Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, where the combination for the study and the diagnosis of lymphoproliferative diseases is: CD19 CD20, CD5, CD23, CD38, FMC7 CD79b. 4.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, where the combination for the study of Multiple Sclerosis is: CD3 CD8 CCR7 CD45RA CD11a CD62L CD27. δ.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that this method can be used both on whole blood and on peripheral blood mononuclear cells purified with a gradient. Briefly, heparinized blood is diluted with 1 volume of RPMI media and gently
layered over the Fycoll-Hypaque (Pharmacia). Following centrifugation at 660g for 30 minutes, cells at the interface of the gradient will be collected and washed three times in medium. After the final wash cells are resuspended in PBS with 1% human serum. For each labelling 5 cells are resuspended in a volume of 100 μl. 6. Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that for the study of cytokine production the technique of ιo intracellular staiinng is performed, by which cells are plated at a density of 2x106/ml in 96 well plates and triggered with either mitogens (PHA, PMA+ionomycin) or antibodies directed against cell surface molecules (such as CD3), for 6 hours at 37°C, in the presence of monensin (10 mM). At the end of the incubation period, cells will be5 collected, spun, and staining of extracellular markers will be performed, followed by two washes. Samples will then be fixed with 4% paraformaldehyde in PBS for 10 min at 40C, and permeabilized by washing twice with a solution containing PBS (without Ca++ and Mg++), 1% FBS, and 0.1% saponin at pH 7.4. Cells will beo resuspended in permeabilization buffer plus fluorochrome-conjugated anticytokine antibody (1 Dg per ml) for 30 miri at 4°C in the dark. Cells will be washed twice, resuspended in 250 μl of staining buffer (PBS, 1% FBS, 0.01% sodium azide) and analyzed by FACS.
Claims
1. Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases. This method is characterized by the ability to use different fluorochrome-conjugated antibody combinations which enable to perform an analysis of the individual's immunological status; the antibodies are aliquoted in predetermined concentrations and lyophilized. At the moment of use, each antibody combination is reconstituted by the addition of saline solution, and added to the tube containing the cells to be analyzed. For each antibody combination 2x106 cells are stained. Each antibody is tested and used in saturating concentration so as to avoid differences in sample staining. Samples are then analyzed at the flow cytometer using constant instrument setting obtained with a careful daily calibration with beads. For each sample 1x106 events are acquired in order to achieve an appropriate representation of all cellular subsets and to allow significant statistical analysis.
2.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that the antibodies whose efficacy has been tested are: CD3 PE-Cy7, CD8 PE-Cy7, CD8 PE-TxRed, CD45RA PE-TxRed, CD62L, PE-TxRed, CD45RO PE-TxRed, CD8 beta PE, CD49dFITC, NKRP1A PE, CD3 FITC, CD3 PE, CD8 FITC, CD8 PE, CD8 CyChrome, CD8
APC, CD4 FITC, CD4 APC, CD62L PE-Cy5, CD62L APC, CD162 PE, CCR7 PE, CD45RO FITC, CD11a PE, CD11a APC, CD49d PE, CD8 APC-Cy7, CD11a FITC, CD45RA PE-Cy5, CD5 PE-Cy5, CD23 PE- TxRed, CD19 PE-Cy7, CD19 APC-Cy7, CD79b APC, CD38 PE, kappa FITC, lambda PE, FMC7 FITC, CD20 PE-Cy7. Two examples of antibody combinations used are: a) for haematological diseases, Mix 1 = CD19 CD20 CD79b, CD5, CD23, CD38, FMC7, and b) for the study of Multiple Sclerosis Mix 2= CD3 CD8 CCR7 CD45RA CD11a CD62L CD27. 3.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, where the combination for the study and the diagnosis of lymphoproliferative diseases is: CD19 CD20, CD5, CD23, CD38, FMC7 CD79b. 4.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, where the combination for the study of Multiple Sclerosis is: CD3 CD8 CCR7 CD45RA CD11a CD62L CD27. β.Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that this method can be used both on whole blood and on peripheral blood mononuclear cells purified with a gradient. Briefly, heparinized blood is diluted with 1 volume of RPMI media and gently
layered over the Fycoll-Hypaque (Pharmacia). Following centrifugation at 660g for 30 minutes, cells at the interface of the gradient will be collected and washed three times in medium. After the final wash cells are resuspended in PBS with 1% human serum. For each labelling cells are resuspended in a volume of 100 μl.
6. Method for the use of multiparametric flow cytometry for the prognosis and the validation of immunotherapies of autoimmune and haematological diseases, as described above, and characterized by the fact that for the study of cytokine production the technique of intracellular staiinng is performed, by which cells are plated at a density of 2x106/ml in 96 well plates and triggered with either mitogens (PHA, PMA+ionomycin) or antibodies directed against cell surface molecules (such as CD3), for 6 hours at 37°C, in the presence of monensin (10 m ). At the end of the incubation period, cells will be collected, spun, and staining of extracellular markers will be performed, followed by two washes. Samples will then be fixed with 4% paraformaldehyde in PBS for 10 min at 40C, and permeabilized by washing twice with a solution containing PBS (without Ca++ and Mg++), 1% FBS, and 0.1% saponin at pH 7.4. Cells will be resuspended in permeabilization buffer plus fluorochrome-conjugated anticytokine antibody (1 Dg per ml) for 30 min at 4°C in the dark. Cells will be washed twice, resuspended in 250 μl of staining buffer (PBS, 1% FBS, 0.01% sodium azide) and analyzed by FACS.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04745177A EP1842068A1 (en) | 2004-06-21 | 2004-06-21 | Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases |
| PCT/IT2004/000352 WO2005124350A1 (en) | 2004-06-21 | 2004-06-21 | Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2004/000352 WO2005124350A1 (en) | 2004-06-21 | 2004-06-21 | Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005124350A1 true WO2005124350A1 (en) | 2005-12-29 |
Family
ID=34957987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IT2004/000352 WO2005124350A1 (en) | 2004-06-21 | 2004-06-21 | Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP1842068A1 (en) |
| WO (1) | WO2005124350A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102062774A (en) * | 2009-11-13 | 2011-05-18 | 程小星 | Kit for detecting tuberculosis treatment effect |
| US8148101B2 (en) | 2008-07-22 | 2012-04-03 | Abbott Laboratories | Method for classifying and counting bacteria in body fluids |
| WO2014135924A1 (en) * | 2013-03-08 | 2014-09-12 | Cells For Cells | Menstrual stems cells for the efficient support and expansion of cd34+ cd133+ hematopoietic stem cells in vitro |
| CN109030322A (en) * | 2018-08-17 | 2018-12-18 | 成都赋智健康科技有限公司 | A kind of flow cytometry assays of save the cost |
| CN110412286A (en) * | 2019-07-11 | 2019-11-05 | 上海宸安生物科技有限公司 | A method of Single cell analysis being carried out to tumor sample using mass spectrum streaming systems |
| CN110488009A (en) * | 2019-04-12 | 2019-11-22 | 北京市理化分析测试中心 | A kind of detection method and application of the immune function of human body of non-disease diagnostic purpose |
| CN111316098A (en) * | 2017-09-15 | 2020-06-19 | 拜克门寇尔特公司 | Flow-based assays for therapy |
| CN111527395A (en) * | 2018-12-01 | 2020-08-11 | 铭道创新（北京）医疗技术有限公司 | Flow cytometry detection method for lymphocytes in immune cells |
| CN114112868A (en) * | 2020-08-26 | 2022-03-01 | 上海睿昂基因科技股份有限公司 | Flow cytometry kit for monitoring tumor-related immune microenvironment and monitoring method |
| WO2023115702A1 (en) * | 2021-12-22 | 2023-06-29 | 重庆医科大学附属儿童医院 | Method and kit for immunotyping of t lymphocyte development subgroups |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995020054A1 (en) * | 1994-01-21 | 1995-07-27 | Coulter Corporation | Solid tumor analysis by multiparametric flow cytometry |
| WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
-
2004
- 2004-06-21 EP EP04745177A patent/EP1842068A1/en not_active Withdrawn
- 2004-06-21 WO PCT/IT2004/000352 patent/WO2005124350A1/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995020054A1 (en) * | 1994-01-21 | 1995-07-27 | Coulter Corporation | Solid tumor analysis by multiparametric flow cytometry |
| WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
Non-Patent Citations (12)
| Title |
|---|
| BAUMGARTH N ET AL: "A practical approach to multicolor flow cytometry for immunophenotyping", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 243, no. 1-2, 21 September 2000 (2000-09-21), pages 77 - 97, XP004210694, ISSN: 0022-1759 * |
| BRAYLAN RAUL C ET AL: "Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting", CYTOMETRY, vol. 46, no. 1, 15 February 2001 (2001-02-15), pages 23 - 27, XP009050615, ISSN: 0196-4763 * |
| DE ROSA STEPHEN C ET AL: "11-Color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity", NATURE MEDICINE, vol. 7, no. 2, February 2001 (2001-02-01), pages 245 - 248, XP002323311, ISSN: 1078-8956 * |
| DE ROSA STEPHEN C ET AL: "Beyond six colors: A new era in flow cytometry.", NATURE MEDICINE, vol. 9, no. 1, January 2003 (2003-01-01), pages 112 - 117, XP001205960, ISSN: 1078-8956 * |
| GIUNTI D ET AL: "PHENOTYPIC AND FUNCTIONAL ANALYSIS OF T CELLS HOMING INTO THE CSF OF SUBJECTS WITH INFLAMMATORY DISEASES OF THE CNS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 73, no. 5, May 2003 (2003-05-01), pages 584 - 590, XP009045988, ISSN: 0741-5400 * |
| HULKKONEN J ET AL: "Surface antigen expression in chronic lymphocytic leukemia: Clustering analysis, interrelationships and effects of chromosomal abnormalities", LEUKEMIA (BASINGSTOKE), vol. 16, no. 2, February 2002 (2002-02-01), pages 178 - 185, XP002336335, ISSN: 0887-6924 * |
| KALEEM ZAHID ET AL: "Flow cytometric evaluation of posttransplant B-cell lymphoproliferative disorders.", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. FEB 2004, vol. 128, no. 2, February 2004 (2004-02-01), pages 181 - 186, XP002323312, ISSN: 1543-2165 * |
| KERN WOLFGANG ET AL: "Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.", HAEMATOLOGICA. MAY 2004, vol. 89, no. 5, May 2004 (2004-05-01), pages 528 - 540, XP009045458, ISSN: 1592-8721 * |
| PAIETTA ELISABETH: "How to optimize multiparameter flow cytometry for leukaemia/lymphoma diagnosis.", BEST PRACTICE & RESEARCH. CLINICAL HAEMATOLOGY. DEC 2003, vol. 16, no. 4, December 2003 (2003-12-01), pages 671 - 683, XP009045457, ISSN: 1521-6926 * |
| PERFETTO STEPHEN P ET AL: "New advances in flow cytometry: How to do successful polychromatic flow cytometry", CYTOMETRY, vol. 59A, no. 1, May 2004 (2004-05-01), & XXII CONGRESS OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY, pages 98 - 99, XP009045469, ISSN: 0196-4763 * |
| RASPADORI DONATELLA ET AL: "Progressed B-CLL patients are not associated by immunophenotypic modifications", BLOOD, vol. 96, no. 11 Part 2, 16 November 2000 (2000-11-16), & 42ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; SAN FRANCISCO, CALIFORNIA, USA; DECEMBER 01-05, 2000, pages 281b, XP009050646, ISSN: 0006-4971 * |
| SERKE S ET AL: "Imprecision of counting CFU-GM colonies and CD34-expressing cells", BONE MARROW TRANSPLANTATION, vol. 20, no. 1, 1997, pages 57 - 61, XP002323313, ISSN: 0268-3369 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148101B2 (en) | 2008-07-22 | 2012-04-03 | Abbott Laboratories | Method for classifying and counting bacteria in body fluids |
| CN102062774A (en) * | 2009-11-13 | 2011-05-18 | 程小星 | Kit for detecting tuberculosis treatment effect |
| WO2014135924A1 (en) * | 2013-03-08 | 2014-09-12 | Cells For Cells | Menstrual stems cells for the efficient support and expansion of cd34+ cd133+ hematopoietic stem cells in vitro |
| CN111316098A (en) * | 2017-09-15 | 2020-06-19 | 拜克门寇尔特公司 | Flow-based assays for therapy |
| CN111316098B (en) * | 2017-09-15 | 2024-05-14 | 拜克门寇尔特公司 | Flow-based assays for treatment |
| CN109030322A (en) * | 2018-08-17 | 2018-12-18 | 成都赋智健康科技有限公司 | A kind of flow cytometry assays of save the cost |
| CN111527395A (en) * | 2018-12-01 | 2020-08-11 | 铭道创新（北京）医疗技术有限公司 | Flow cytometry detection method for lymphocytes in immune cells |
| CN111527395B (en) * | 2018-12-01 | 2024-01-26 | 铭道创新（北京）医疗技术有限公司 | Flow cytometry detection method for lymphocytes in immune cells |
| CN110488009A (en) * | 2019-04-12 | 2019-11-22 | 北京市理化分析测试中心 | A kind of detection method and application of the immune function of human body of non-disease diagnostic purpose |
| CN110488009B (en) * | 2019-04-12 | 2023-09-05 | 北京市理化分析测试中心 | Detection method and application of human immune function for non-disease diagnosis purpose |
| CN110412286A (en) * | 2019-07-11 | 2019-11-05 | 上海宸安生物科技有限公司 | A method of Single cell analysis being carried out to tumor sample using mass spectrum streaming systems |
| CN114112868A (en) * | 2020-08-26 | 2022-03-01 | 上海睿昂基因科技股份有限公司 | Flow cytometry kit for monitoring tumor-related immune microenvironment and monitoring method |
| WO2023115702A1 (en) * | 2021-12-22 | 2023-06-29 | 重庆医科大学附属儿童医院 | Method and kit for immunotyping of t lymphocyte development subgroups |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1842068A1 (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sewell et al. | Determination of intracellular cytokines by flow-cytometry following whole-blood culture | |
| EP0559738B1 (en) | Methods for detection and quantitation of cell subsets within subpopulations of a mixed cell population | |
| Esparza et al. | Neutrophil function in elderly persons assessed by flow cytometry | |
| JP4435948B2 (en) | Leukocyte classification and counting method | |
| US5156951A (en) | Detecting immunological changes in HIV infected patient samples | |
| JP2004533855A (en) | Cell counting | |
| US6630316B1 (en) | Method for measurement of lymphocyte function | |
| WO2005124350A1 (en) | Use of multiparametric flow cytometry for the diagnosis, prognosis, and validation of immunotherapies in autoimmune, hematologic, and lymphoproliferative diseases | |
| Terstappen et al. | Physical discrimination between human T‐lymphocyte subpopulations by means of light scattering, revealing two populations of T8‐positive cells | |
| CN115166252A (en) | Lymphocyte subset grouping and quantitative detection kit, detection method and application thereof | |
| EP2453243A1 (en) | Method for the diagnosis and/or follow up of the evolution of a tumor | |
| Prince et al. | CD69 expression reliably predicts the anti-CD3-induced proliferative response of lymphocytes from human immunodeficiency virus type 1-infected patients | |
| Lenkei et al. | Indicators of T‐cell activation: Correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls | |
| US5968755A (en) | Methods for determining T-cell profiles of immunocompromised subjects | |
| CN111504886A (en) | Application of a group of molecules in preparation of auxiliary diagnosis reagent or kit for new coronary pneumonia | |
| US7169571B2 (en) | Methods for measurement of lymphocyte function | |
| Lavigne et al. | Identification and analysis of eosinophils by flow cytometry using the depolarized side scatter‐saponin method | |
| AU764745B2 (en) | Use of an antibody to detect basophiles and/or mast cells | |
| Hutchinson et al. | Mitogen‐induced T‐cell CD69 expression is a less sensitive measure of T‐cell function than [3H]‐thymidine uptake | |
| US20040110122A1 (en) | Three-color reagent for measurement of CD4 positive lymphocytes by flow cytometry | |
| El‐Awar et al. | Discrimination of T, B, and Null Lymphocytes by Electronic Sizing1 | |
| US20070243576A1 (en) | Method to confirm immunosuppression in human patients by measuring lymphocyte activation | |
| BIOLOGORUM | Detection of intracellular cytokines in human lymphocytes and monocytes at the single cell level by flow cytometry | |
| Prince et al. | Simultaneous determination of absolute total lymphocyte and CD4+ lymphocyte levels in peripheral blood by flow cytometry | |
| CN107860907A (en) | Application of the albumen of Pru p 3 in wormwood artemisia pollen correlation peach allergy detection kit is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004745177 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004745177 Country of ref document: EP |